Luitpold Animal Health, the maker of the injectable joint medication Adequan, will ring in the new year by unveiling a new name.
Starting Jan. 1, Luitpold Animal Health will be known as American Regent Animal Health. The name change will occur as Luitpold absorbs two subsidiaries, American Regent Inc. and PharmaForce Inc.
“While our company name is changing, all customer service, manufacturing, sales and distribution channels will remain the same,” said Joel Steckler, vice president of commercial operations.
The switch reflects a “commitment to animal health while unifying the company under a common set of values, goals and operating principles,” Luitpold stated.
Adequan i.m. for horses was introduced in 1989 and Adequan Canine (polysulfated glycosaminoglycan) in 1997.
Adequan i.m. is indicated for the intramuscular treatment of non-infectious degenerative or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. The canine version is recommended for the control of signs associated with non-infectious degenerative or traumatic arthritis of synovial joints.
Adequan Canine returned to Luitpold in April 2018 after being licensed to and manufactured by Novartis Animal Health and later Elanco Animal Health.
Luitpold Animal Health is headquartered in Shirley, New York.